{"schema":"sb.node.v1","id":"sb:e/ad36eec85e99991db77551a8","kind":"entity","label":{"text":"glp-1s","locale":"en"},"identity":{"anchor":"label:en:glp-1s","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-09T23:33:39.923351+00:00","snapshot":"deploy 760ddad45b80bcc53aa1d7d4c2af0dae14c85403"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":81,"separatePublishers":46,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":1,"named":11,"of":11,"basis":"receipts the entity graph keeps whose own headline names the subject, over all receipts it keeps for the subject (the door's measurement; the graph carries none of its own). Only the former are served"}},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-04-06","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.16: about 84% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto","biotech_pharma"],"activeDays":26,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/cc1f3175bcf5010a7fa01d58","kind":"observation","label":"MarketWatch · 2026-10-08 · GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution","url":"https://www.marketwatch.com/story/glp-1s-could-offer-unexpected-relief-from-back-and-knee-pain-but-doctors-urge-caution-b0de1609?mod=mw_rss_topstories"},{"id":"sb:o/cb4748f078eada1a142db19e","kind":"observation","label":"Fast Company · 2026-10-01 · Hershey CEO Kirk Tanner on GLP-1s, AI, and keeping an iconic brand relevant","url":"https://www.fastcompany.com/91616020/hershey-ceo-kirk-tanner-on-glp-1s-ai-and-keeping-an-iconic-brand-relevant"},{"id":"sb:o/8019ed73800598e535d2d5be","kind":"observation","label":"Fortune · 2026-10-01 · Forget supersized: McDonald’s is exploring an $8.5 billion bet on an American fast food wave led by proteinmaxxing, portion control, and GLP-1s","url":"https://fortune.com/2026/10/01/mcdonalds-8-5-billion-bet-fast-food-protein-glp-1/"},{"id":"sb:o/42cdadb6230b121677a9542a","kind":"observation","label":"Clinical Trials Arena · 2026-10-01 · EASD 2026: Oral semaglutide drives weight loss after switch from injectable GLP-1s","url":"https://www.clinicaltrialsarena.com/analyst-comment/easd-2026-oral-semaglutide-drives-weight-loss-after-switch-from-injectable-glp-1s/"},{"id":"sb:o/da26b5a798b022e974d17ed9","kind":"observation","label":"ABC News AU business · 2026-10-01 · Doctors condemn big pharma's move to dispense GLP-1s to your door","url":"https://www.abc.net.au/news/2026-10-01/backlash-over-eli-lilly-mounjaro-delivery/107211964"},{"id":"sb:o/3455378ae89397041503ee36","kind":"observation","label":"Fierce Pharma · 2026-09-30 · Novo, Lilly pit their GLP-1s against one another in diabetes and obesity as EASD kicks off in Milan","url":"https://www.fiercepharma.com/pharma/novo-lilly-pit-their-glp-1s-against-one-another-diabetes-and-obesity-easd-kicks-milan"},{"id":"sb:o/55b3c88976df52f9fdc07045","kind":"observation","label":"STAT News · 2026-09-29 · STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more","url":"https://www.statnews.com/pharmalot/2026/09/28/glp1-lifestyle-drug-marketing-merck-daiichi-lung-cancer-setback/?utm_campaign=rss"},{"id":"sb:o/3568674abae3447c80809e91","kind":"observation","label":"Fierce Pharma · 2026-09-29 · Eli Lilly's new initiative will take GLP-1s to lower-income nations","url":"https://www.fiercepharma.com/pharma/lillys-new-initiative-will-take-glp-1s-lower-income-nations"},{"id":"sb:o/78ca8ed790d65fe595070ebb","kind":"observation","label":"STAT News · 2026-09-28 · STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’","url":"https://www.statnews.com/2026/09/28/glp1-marketing-shift-obesity-medicine-weight-loss-drug/?utm_campaign=rss"},{"id":"sb:o/2d45253463154e18400f5fb1","kind":"observation","label":"The Medical News · 2026-09-24 · GLP-1s linked to nutritional deficiencies in children","url":"https://www.news-medical.net/news/20260924/GLP-1s-linked-to-nutritional-deficiencies-in-children.aspx"}],"cursor":"c1.eyJpZCI6InNiOmUvYWQzNmVlYzg1ZTk5OTkxZGI3NzU1MWE4IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA5VDIzOjMzOjM5LjkyMzM1MSswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity whose own headline names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with glp-1 (81 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b7bf40cafc38451ad9cfa045"},{"kind":"relation","label":"co-mentioned with fda (29 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/84986e2512c6a0d7f5070da9"},{"kind":"relation","label":"co-mentioned with eli lilly (26 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/856c8bb82d0d1f1522ef47aa"},{"kind":"relation","label":"co-mentioned with studie (20 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/aabd32d08b24b9fe39b8d68a"},{"kind":"relation","label":"co-mentioned with ai (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/5ca4b90e53288a483d5047c1"},{"kind":"relation","label":"co-mentioned with novo nordisk (16 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/f73ea7396ec38d6cb3788bad"},{"kind":"relation","label":"co-mentioned with americans (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/ccfa58bd18a4ebb8e8dc80cb"},{"kind":"relation","label":"co-mentioned with mounjaro (14 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2114ce02b1179dfcf08de199"},{"kind":"relation","label":"co-mentioned with zepbound (14 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/ffef98eef7f4f1e6d6ce3e4a"},{"kind":"relation","label":"co-mentioned with clinical trials (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/29a8352f07146a6b3fa9df7c"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/ad36eec85e99991db77551a8","mcp":"traverse {\"id\":\"sb:e/ad36eec85e99991db77551a8\"}","page":"/entity/glp-1s/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/ad36eec85e99991db77551a8\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/ad36eec85e99991db77551a8\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/ad36eec85e99991db77551a8\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/ad36eec85e99991db77551a8\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}